Can T Stop a Bull Limits of Claim Preclusion
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Cesar A. Estrada & Jeremy Anapol
INGURAN, LLC, DBA STGENETICS v. ABS GLOBAL, INC., GENUS PLC
Before Lourie, Bryson, and Reyna. Appeal from the United States District Court for the Western District of Wisconsin.
Summary: Claim preclusion does not bar an induced infringement claim that did not exist at the time of the earlier action.
In a first lawsuit (ABS I), STGenetics (“ST”) brought claims for patent infringement against ABS Global, Inc. (“ABS”). ABS stipulated that its GSS System directly infringed ST’s patent on a method for sorting bull sperm cells. The district court granted ST an ongoing royalty. ST also filed a second patent infringement suit (ABS II) against ABS. During discovery in ABS II, ST learned that ABS had begun selling and licensing the GSS System to third parties and teaching them how to use the system. In a third suit (ABS III), ST alleged induced infringement based on ABS’s selling and licensing of the GSS System to third parties. ABS moved to dismiss this induced infringement claim on the ground that the claim was precluded by the judgement in ABS I. The district court granted the motion to dismiss. ST appealed.
On appeal, ABS and ST disputed only the second element of the three elements to claim preclusion, namely whether ABS I and ABS III involved the same cause of action. The Federal Circuit first found that, in ABS I, ST did not assert induced infringement involving third parties. Second, the Federal Circuit found that ST could not have tried its third-party induced-infringement claim in ABS I because such claim would have been based on speculation and the facts supporting the claim came to light only during discovery in ABS II. For these reasons, the Federal Circuit held that ABS I and ABS III did not involve the same cause of action. Thus, the district court erred in applying claim preclusion and the Federal Circuit reversed.
Editor: Paul Stewart
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…